Comparative Pharmacology
Head-to-head clinical analysis: PROMETH FORTIS versus TAVIST 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETH FORTIS versus TAVIST 1.
PROMETH FORTIS vs TAVIST-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, with additional anticholinergic, antiemetic, and sedative properties. It blocks histamine at H1 receptors, reducing allergic symptoms and motion sickness, and exerts antiemetic effects by blocking dopamine D2 receptors in the chemoreceptor trigger zone.
TAVIST-1 (clemastine fumarate) is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
Adults: 12.5-25 mg intramuscular or intravenous every 4-6 hours as needed for nausea. For severe nausea up to 50 mg IM/IV. Maximum single dose 50 mg, maximum daily dose 200 mg.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
Terminal elimination half-life: 9–16 hours (mean ~12 hours). In children and elderly, half-life may be prolonged (up to 20 hours).
Terminal half-life 12–15 hours; clinical dosing interval every 12 hours.
Primarily renal as inactive metabolites; <1% excreted unchanged. Total elimination: renal ~70%, fecal ~30%.
Primarily renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; minor via feces.
Category C
Category C
Antihistamine
Antihistamine